Literature DB >> 2056516

Human lactoferrin binding in clinical isolates of Staphylococcus aureus.

A S Naidu1, J Miedzobrodzki, J M Musser, V T Rosdahl, S A Hedström, A Forsgren.   

Abstract

Human lactoferrin (HLf) is an iron-binding protein and a host-defence component at the mucosal surface. Recently, a specific receptor for HLf has been identified on a strain of Staphylococcus aureus associated with toxic shock syndrome. We have looked for the occurrence of 125I-HLf binding among 489 strains of S. aureus isolated from various clinical sources. HLf binding was common among S. aureus strains associated with furunculosis (94.3%), toxic shock syndrome (94.3%), endocarditis (83.3%) and septicaemia (82.8%) and other (nasal, vaginal or ocular) infections (96.1%) with a mean binding (in fmol) of 29.1, 21.9, 16.9, 22.2 and 29.2 respectively; the differences between mean HLf binding values of 29.1-29.2, 21.9-22.2 and 16.9 were significant. Furunculosis-associated (low-invasive or localised) isolates were high-to-moderate binders of HLf; 50% gave positive results at a threshold of greater than 31 fmol of 125I-HLf bound. In contrast, endocarditis-associated (high-invasive or systemic) isolates demonstrated low binding and did not bind 125I-HLf at the above threshold level. S. aureus recognised human or bovine Lf. However, bound 125I-HLf was more effectively inhibited in a dose-dependent manner by unlabelled bovine Lf than by homologous HLf. Binding of 125I-HLf to staphylococci was optimal with organisms grown in agar compared with those from broth cultures. The binding capacity of S. aureus was abolished when strains were grown on carbohydrate- and salt-rich agar media. HLf-binding ability of S. aureus did not correlate with fibronectin, fibrinogen, immunoglobulin G or laminin binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056516     DOI: 10.1099/00222615-34-6-323

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

1.  Clusterin, a putative complement regulator, binds to the cell surface of Staphylococcus aureus clinical isolates.

Authors:  S R Partridge; M S Baker; M J Walker; M R Wilson
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

2.  Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium.

Authors:  S S Naidu; U Svensson; A R Kishore; A S Naidu
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

3.  Acquisition of iron from transferrin and lactoferrin by the protozoan Leishmania chagasi.

Authors:  M E Wilson; R W Vorhies; K A Andersen; B E Britigan
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

4.  Staphylococcal iron requirements, siderophore production, and iron-regulated protein expression.

Authors:  J A Lindsay; T V Riley
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

5.  Lactoferrin binds to porins OmpF and OmpC in Escherichia coli.

Authors:  J Erdei; A Forsgren; A S Naidu
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

6.  Lactoferrin-binding proteins in Shigella flexneri.

Authors:  Z Tigyi; A R Kishore; J A Maeland; A Forsgren; A S Naidu
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

7.  Correlation between human lactoferrin binding and colicin susceptibility in Escherichia coli.

Authors:  I Gadó; J Erdei; V G Laszlo; J Pászti; E Czirók; T Kontrohr; I Tóth; A Forsgren; A S Naidu
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

8.  Antimicrobial Functions of Lactoferrin Promote Genetic Conflicts in Ancient Primates and Modern Humans.

Authors:  Matthew F Barber; Zev Kronenberg; Mark Yandell; Nels C Elde
Journal:  PLoS Genet       Date:  2016-05-20       Impact factor: 5.917

Review 9.  Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli.

Authors:  Fabiana Superti; Francesco De Seta
Journal:  Microorganisms       Date:  2020-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.